NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) – Pomerantz LLP is investigating claims on behalf of investors in BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN). It is recommended that such investors contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529 extension 1. 7980.
The investigation concerns whether BioMarin and any of its officers and / or directors have committed securities fraud or other illegal business practices.
(Click here for information on how to participate in the class action.)
On August 19, 2020, BioMarin announced that it has received a full response letter (“CRL”) from the US Food and Drug Administration (“FDA”) to the Company's Biologics license application for valoctocogen roxaparvovec gene therapy for severe hemophilia. A. BioMarin advised investors that in the CRL, “The FDA has introduced a new recommendation for two years of data from the company's ongoing 270-301 trial (Phase 3) to provide substantial evidence of lasting effect using the Annualized Bleeding Rate (ABR) as the primary endpoint "and" Recommended that the company complete the Phase 3 study and provide two-year data on the safety and efficacy of all study participants. " In this news, BioMarin's stock price fell sharply during intraday trading on August 19, 2020.
The Pomerantz firm, with offices in New York, Chicago, Los Angeles and Paris, is recognized as one of the leading law firms in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, dean of class action lawsuit, Pomerantz pioneered class action lawsuits. Today, more than 80 years later, Pomerantz continues its tradition and fights for the rights of victims of securities fraud, fiduciary violations and corporate misconduct. The company has received numerous millions of dollars in damages on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby